Clinical trial · Interventional
Efficacy of Topical Coenzyme Q10 and Curcumin for Oral Leukoplakia Treatment
Clinical and Biochemical Assessment of the Effectivness of Topical Coenzyme Q10 and Topical Curcumin in Managment of Oral Leukoplakia (A Randomized Controlled Clinical Trial)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Oral leukoplakia (OL) is recognized as the most common potentially malignant disorder of the oral mucosa. The pathogenesis of OL is complex and multifactorial, with oxidative stress playing a central role. Topical antioxidants have gained attention as therapeutic options to help stabilize lesions and potentially prevent malignant transformation. Both CoQ10 and curcumin have demonstrated a clinical success as strong antioxidants showing their capacity to reduce the lesion size and to stabilize the disease, ultimately preventing progression into oral malignancy. Aim: This study aims to clinically and biochemically assess the effectiveness of topical Coenzyme Q10 and Curcumin in the management of homogeneous oral leukoplakia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oral Leukoplakia | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Coenzyme Q10 gel | Other | — | UNRESOLVED |
| Topical curcumin gel | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Topical Coenzyme Q10 gel
- interventionNames
- Other: Coenzyme Q10 gel
- type
- EXPERIMENTAL
- label
- Topical curcumin gel
- interventionNames
- Other: Topical curcumin gel
Primary outcomes (1)
- measure
- Change in lesion size
- timeFrame
- baseline, 4 weeks, and 12 weeks
- description
- measured clinically with a periodontal probe and/or digital images
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Clinically and histologically diagnosed with homogeneous oral leukoplakia not indicated for surgical excision . * Lesions accessible for topical application. * Willing to sign informed consent and comply with study instructions and return to follow up Exclusion Criteria: * Moderate-to-severe dysplasia, carcinoma in situ, or invasive oral cancer. * Presence of any visible oral lesions except for oral leukoplakia. * Active periodontal diseases as this can confound salivary biomarkers. * Significant systemic illness or immunosuppression. * Patients who have taken systemic or topical antioxidant supplements within the last four weeks will be excluded to avoid confounding effects on salivary biomarkers. * Pregnant and lactating women will be excluded due to hormonal changes that may alter oxidative stress and ethical considerations. * Patients unwilling or unable to comply with study requirements.
References
Publications (0)
Data not yet available